Breaking: Capricor Therapeutics, Inc. (CAPR) Spike Almost 400% The share price of Capricor Therapeutics, Inc. (CAPR) saw a noteworthy uptick of almost 400% in Wednesday's market session breaking out of a bullish flag pattern. The asset is gearing for a move to the $50 resistant amidst market condition.
In another recent news, which could be the precursor to the recent surge, Capricor Therapeutics ( NASDAQ:CAPR ), said on Wednesday its cell therapy for a rare muscular disorder met the main goal of a late-stage study, reviving hopes for U.S. approval after a setback and sending its shares up more than four-fold.
Shares of the San Diego-based company soared 328% to $27.25, on track to add about $955 million in market value, if gains hold.
Financial Performance
In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
